Movement Alert｜Praxis Precision Medicines, Inc. Pre-Market Rise 5.48% in Pre-Market Trading, FDA Grants Breakthrough Therapy Designation to elsunersen

Market Focus10-19

On October 19, Praxis Precision Medicines, Inc. rose 5.48% in Pre-Market Trading, trading at 255.0 USD/share, with turnover of 64.2 thousand USD.

The move followed the company’s disclosure that the FDA granted Breakthrough Therapy designation to elsunersen for seizures associated with SCN2A developmental and epileptic encephalopathy caused by gain-of-function SCN2A variants.

elsunersen is an antisense oligonucleotide therapy designed to selectively reduce SCN2A gene expression and directly target the disease mechanism in early-onset epileptic SCN2A-DEE. The designation adds regulatory momentum to Praxis Precision Medicines, Inc.’s rare disease neurology pipeline. Earlier company updates had also highlighted a review delay for relutrigine and clinical progress for vormatrigine, indicating continued pipeline advancement.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment